Engineered immune cells take on lupus and scleroderma in first human test
NCT ID NCT06255028
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't improved with standard therapies. CNTY-101 uses specially engineered immune cells to target and destroy faulty B cells that drive the disease. The main goals are to check safety and find the right dose, with only 6 participants enrolled so far.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CNTY-101 (a type of immune cell therapy) with or without IL-2 and chemotherapy
What this could lead to
If it works, this could point toward a new treatment option for people with severe autoimmune diseases that haven't responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 6 participants, so it's mainly testing safety and dosing. The treatment may not work, and there are risks like cytokine release syndrome and other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch
Seattle, Washington, 98109, United States
-
Keck School of Medicine of University of Southern California
Los Angeles, California, 90033, United States
-
Lurie Children's; Northwestern Medicine - Northwestern Medical Group
Chicago, Illinois, 60611, United States
-
Primary Children's Hospital
Salt Lake City, Utah, 84113, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
-
UC Davis
Sacramento, California, 957817, United States